Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Sarcoma 2Vulvar Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 4pembrolizumab 3Docetaxel 3Cryosurgery 3Biopsy 3eribulin 2durvalumab 2balstilimab 2atezolizumab 2aflibercept 2Zoledronic Acid 2Trastuzumab 2Taxes 2Specimen Handling 2Radiotherapy 2Radiosurgery 2Radiation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Letrozole 2Irinotecan 2Gene Expression Profiling 2Fulvestrant 2Cisplatin 2Blood Specimen Collection 2Bevacizumab 2130-nm albumin-bound paclitaxel 2trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × tivozanib × Sarcoma × Clear all
NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡